Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "UPI"

510 News Found

Lupin receives tentative approval for Brexpiprazole tablets
Drug Approval | October 06, 2021

Lupin receives tentative approval for Brexpiprazole tablets

This product will be manufactured at Lupin’s Pithampur facility In India


Merck and Ridgeback’s molnupiravir offer hope to Covid-19 patients
Biotech | October 01, 2021

Merck and Ridgeback’s molnupiravir offer hope to Covid-19 patients

If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic


Lupin launches Droxidopa capsules in the US
Drug Approval | September 29, 2021

Lupin launches Droxidopa capsules in the US

Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA


U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations
News | September 20, 2021

U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations

The company said in a regulatory filing that it was confident of addressing the observations satisfactorily


Lupin to settle litigations over diabetes drug
News | September 16, 2021

Lupin to settle litigations over diabetes drug

The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval


Lupin launch a generic version of pain reliever for osteoarthritis in the US
Drug Approval | September 15, 2021

Lupin launch a generic version of pain reliever for osteoarthritis in the US

Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21


TB Alliance partners with Lupin for non-exclusive anti-TB drug
Policy | September 06, 2021

TB Alliance partners with Lupin for non-exclusive anti-TB drug

According to WHO, over 1.5 million people died of TB in 2020


Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
Drug Approval | September 01, 2021

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab

JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Lupin launches Luforbec to treat asthma & COPD in UK
News | August 24, 2021

Lupin launches Luforbec to treat asthma & COPD in UK

It is the first branded generic alternative to Fostair 100/6 pMDI